Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Issue 32 (31st July 2015)

• Record Type: Journal Article
• Authors: Wu, Ting; Hu, Yue-Mei; Li, Juan; Chu, Kai; Huang, Shou-Jie; Zhao, Hui; Wang, Zhong-Ze; Yang, Chang-Lin; Jiang, Han-Min; Wang, Yi-Jun; Lin, Zhi-Jie; Pan, Hui-Rong; Sheng, Wei; Wei, Fei-Xue; Li, Shao-Wei; Wang, Ying; Zhu, Feng-Cai; Li, Chang-Gui; Zhang, Jun; Xia, Ning-Shao
• Is Part Of: Vaccine. Volume 33:Issue 32(2015)
• Page Start: 3940
• Page End: 3946
• Publication Date: 2015-07-31
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.06.052
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">A dose-ranging study of a novel <italic>E. coli-</italic>expressed HPV 16/18 vaccine candidate.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">This is the first study of the immunogenicity of this recombinant HPV 16/18 vaccine.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">This vaccine was well-tolerated and appeared immunogenic in young women aged 18–25.</p> </list-item> </list> </p> </sec> </abstract>